Moleculin Biotech, Inc.（简称Moleculin）近日公布了其2/3期“Miracle”临床试验的中期分析结果，数据表现积极。结果显示，其核心候选药物Annamycin在诱导完全缓解方面，疗效显著优于对照组，完全缓解率达到了对照组的三倍之高。
这一积极数据为Annamycin在治疗急性髓系白血病领域的后续开发注入了强劲动力。中期分析的成功，意味着该药物在关键疗效指标上取得了突破性进展，有望为患者提供新的治疗选择。公司将继续推进临床试验，以获取更多确证性数据。
Moleculin Biotech, Inc.（简称Moleculin）近日公布了其2/3期“Miracle”临床试验的中期分析结果，数据表现积极。结果显示，其核心候选药物Annamycin在诱导完全缓解方面，疗效显著优于对照组，完全缓解率达到了对照组的三倍之高。
这一积极数据为Annamycin在治疗急性髓系白血病领域的后续开发注入了强劲动力。中期分析的成功，意味着该药物在关键疗效指标上取得了突破性进展，有望为患者提供新的治疗选择。公司将继续推进临床试验，以获取更多确证性数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.